Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 3, 2000, Pages 927-933

  Zorzet, Sonia ^a   Bergamo, Alberta ^b   Cocchietto, Moreno ^b   Sorc, Alenka ^b   Gava, Barbara ^b   Alessio, Enzo ^c   Iengo, Elisabetta ^c   Sava, Gianni ^a,b  

^a Department of Biomedical Sciences ^*  (Italy)

^b Callerio Foundation   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLOROTETRAKISDIMETHYLSULFOXIDE RUTHENIUM; IMIDAZOLE DERIVATIVE; IMIDAZOLIUM IMIDAZOLEDIMETHYLSULFOXIDETETRACHLORORUTHENATE; IMIDAZOLIUM IMIDAZOLETETRACHLORORUTHENATE; MATRIGEL; RUTHENIUM COMPLEX; SODIUM TETRAMETHYLENSULFOXIDEISOQUINOLINETETRACHLORORUTHENATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; COLLAGEN; DIMETHYL SULFOXIDE; DRUG COMBINATIONS; G2 PHASE; HUMANS; LAMININ; MICE; MICE, INBRED C57BL; MITOSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; PROTEOGLYCANS; RUTHENIUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0033694303     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tumor and endothelial cell invasion of basement membranes
2. 4 and related complexes
3. 2SOL
4. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin
5. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulphoxideruthenium compounds and cisplatin detected by flow cytometry
6. Oncological implications of the chemistry of ruthenium
7. Chemical considerations in the design of ruthenium anticancer agents
8. 4 isomers and prevention of brain involvment on P388 leukaemia and on P388/DDP subline
9. 4(DMSO)Im], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma
10. Cytostatic and antitumour properties of a new series of Pt(II) complexes with cyclopentylamine
11. Rapid simultaneous measurement of DNA, protein and cell volume in single cells from large mammalian cell populations
12. Further biologic characteristics of a human carcinoembryonic antigen-producing colon carcinoma cell line
13. Amino acid metabolism in mammalian cell cultures
14. Antitumor activity of some ruthenium derivatives in human colon cancer cell lines in vitro
15. Protocols for screening chemical agents and natural products against animal tumors and other biological systems
16. Antitumor activity of imidazolium bisimidazole tetrachlororuthanate(III)
17. Synthesis, molecular structure, and tumor inhibiting properties of imidazolium transbis(imidazole) tetrachlororuthenate(III) and its methyl-substituted derivatives
18. Antiangiogenic therapy of human esophageal cancers with talidomide in nude mice
19. Chemical, biological and antitumor properties of ruthenium (II) complexes with dimethyl-sulfoxide
20. New salt of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents
21. Rapid calorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
22. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma
23. TS/A: A new metastasizing cell line from BALB/c spontaneous mammary adenocarcinoma
24. Pharmacological control of soIid tumour metastases by ruthenium complexes
25. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex
26. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex
27. 4(DMSO)Im]: Mechanism of the selective action investigated on mouse tumors
28. Treatment of metastases of solid mouse tumours by NAMI-A: Comparison with cisplatin, cyclophosphamide and dacarbazine
29. Effects of ruthenium complexes on experimental tumors: Irrelevance of cytotoxicity for metastasis inhibition
30. Antitumour properties of dimethylsulphoxide ruthenium(II) complexes in the Lewis lung carcinoma system
31. Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice
32. A human cell line from a pleural effusion derived from a breast carcinoma
33. Determination of ruthenium in biological tissue by graphite furnace AAS after solubilizing the sample in tetramethylammonium hydroxide
34. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the biphosphonate ibandronate and tissue inhibitor of the matrix metallo proteinase-2